References
- Christophers E, Mrowietz U. Psoriasis. In: Freedberg IM, Eisen AZ, Wolff K, et al., editors, Dermatology in General Medicine. McGraw-Hill: New York, 2003:407–27.
- Farber EM, Nall L. Natural history and treatment of scalp psoriasis. Cutis 1992;49:396–400.
- Farber EM, Nall ML. The natural history of psoriasis in 5,600 subjects. Dermatologica 1974;148:1–18.
- Koo J. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin 1996;14:485–96.
- Fried RG, Friedman S, Paradis C, et al. Trivial or terrible? The psychosocial impact of psoriasis. Int J Dermatol 1995;34:101–5.
- Van de Kerkhof PC, de Hoop D, de Korte J, Kuipers MV. Scalp psoriasis, clinical presentations and therapeutic man- agement. Dermatology 1998;197:326–34.
- Jegasothy BV. Clobetasol propionate ointment 0.05% versus diflorasone diacetate ointment 0.05% in moderate to severe psoriasis. Int J Dermatol 1990;29:729–30.
- Olsen EA, Cornell RC. Topical clobetasol-17-propionate: review of its clinical efficacy and safety. J Am Acad Dermatol 1986;15:246–55.
- Jacobson C, Cornell RC, Savin RC. A comparison of clobetasol propionate 0.05 percent ointment and an optimized betamethasone dipropionate 0.05 percent oint- ment in the treatment of psoriasis. Cutis 1986;37:213-14, 216218–20.
- Jegasothy B, Jacobson C, Levine N, et al. Clobetasol propionate versus fluocinonide creams in psoriasis and eczema. Int J Dermatol 1985;24:461–5.
- Katz HI, Lindholm JS, Weiss JS, et al. Efficacy and safety of twice-daily augmented betamethasone dipropionate lotion versus clobetasol propionate solution in subjects with moderate-to-severe scalp psoriasis. Clin Ther 1995;17:390–401.
- Olsen EA, Cram DL, Ellis CN, et al. A double-blind, vehicle-controlled study of clobetasol propionate 0.05% (Temovate) scalp application in the treatment of moderate to severe scalp psoriasis. J Am Acad Dermatol 1991; 24:443–7.
- Scott LJ, Dunn CJ, Goa KL. Calcipotriol ointment. A review of its use in the management of psoriasis. Am J Clin Dermatol 2001;2:95–120.
- Mason J, Mason AR, Cork MJ. Topical preparations for the treatment of psoriasis: a systematic review. Br J Dermatol 2002;146:351–64.
- Klaber MR, Hutchinson PE, Pedvis-Leftick A, et al. Comparative effects of calcipotriol solution (50 micro- grams/ml) and betamethasone 17-valerate solution (1 mg/ ml) in the treatment of scalp psoriasis. Br J Dermatol 1994;131:678–83.
- Green C, Ganpule M, Harris D, et al. Comparative effects of calcipotriol (MC903) solution and placebo (vehicle of MC903) in the treatment of psoriasis of the scalp. Br J Dermatol 1994;130:483–7.
- Duweb GA, Abuzariba O, Rahim M, et al. Scalp psoriasis: topical calcipotriol 50 micrograms/g/ml solution vs. betamethasone valerate 1% lotion. Int J Clin Pharmacol Res 2000;20:65–8.
- Thaci D, Daiber W, Boehncke WH, Kaufmann R. Calcipotriol solution for the treatment of scalp psoriasis: evaluation of efficacy, safety and acceptance in 3,396 patients. Dermatology 2001;203:153–6.
- Barnes L, Altmeyer P, Forstrom L, Stenstrom MH. Long- term treatment of psoriasis with calcipotriol scalp solution and cream. Eur J Dermatol 2000;10:199–204.
- Kragballe K, Barnes L, Hamberg KJ, et al. Calcipotriol cream with or without concurrent topical corticosteroid in psoriasis: tolerability and efficacy. Br J Dermatol 1998; 139:649–54.
- Molin L, Cutler TP, Helander I, et al. Comparative efficacy of calcipotriol (MC903) cream and betamethasone 17- valerate cream in the treatment of chronic plaque psoriasis. A randomized, double-blind, parallel group multicentre study. Calcipotriol Study Group. Br J Dermatol 1997; 136:89–93.
- Stoughton RB, Wullich K. Relation of application time to bioactivity of a potent topical glucocorticoid formulation. J Am Acad Dermatol 1990;22:1038–41.